Track AnaptysBio's long-term debt ($280M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), ANAB shows a long-term debt of $280M. That compares with $14M in the prior-year period — up 1921.9% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ANAB's long-term debt is now $280M (was $14M) — a 1921.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether AnaptysBio is outperforming or lagging.
Tracking ANAB's long-term debt over time shows whether AnaptysBio is scaling, shrinking, or reshaping that part of the business. The current reading is $280M That compares with $14M in the prior-year period — up 1921.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has AnaptysBio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $280M) with ownership activity and broader fundamentals.
AnaptysBio's long-term debt is $280M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.